Biolegend, 423106, Zombie NIR™ Fixable Viability Kit, 500tests

Zombie NIR™ is an amine reactive fluorescent dye that is non-permeant to live cells, but permeant to the cells with compromised membranes. Thus, it can be used to assess live vs. dead status of mammalian cells. Zombie NIR™ is a polar water soluble dye, providing red fluorescence, making it suitable for multi-color detection.
500tests
Preparation: Zombie NIR™ Fixable Viability kit is composed of lyophilized Zombie NIR™ dye and anhydrous DMSO. For reconstitution, bring the kit to room temperature; add 100 µl of DMSO to one vial of Zombie NIR™ dye until fully dissolved. 100 tests = 1 vial of Zombie NIR™ + DMSO, 500 tests = 5 vials of Zombie NIR™ + DMSO.
Storage & Handling: Store kit at -20°C upon receipt. Do not open vials until needed. Once the DMSO is added to the Zombie NIR™ dye, use immediately, or store at -20°C in a dry place and protected from light, preferably in a desiccator or in a container with desiccant for no more than one month.
Application: FC - Quality tested
Recommended Usage: Each lot of this product is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometry, the suggested dilution is 1:100-1:1000 for 1-10 million cells. It is recommended that the reagent be titrated for optimal performance for each application, as optimal dosage varies with cell type.
Excitation Laser: Red Laser (633 nm)
Application Notes: Zombie NIR™ dye is excited by the red laser and has fluorescence emission maximum at 746 nm. If using in a multi-color panel design, filter optimization may be required depending on other fluorophores used. Zombie NIR™ dye has similar emission to APC/Cyanine7. Standard Cell Staining Protocol: Prior to reconstitution, spin down the vial of lyophilized reagent in a microcentrifuge to ensure the reagent is at the bottom of the vial. For reconstitution, pre-warm the kit to room temperature; add 100 µL of DMSO to one vial of Zombie NIR™ dye and mix until fully dissolved Wash cells with PBS buffer (no Tris buffer and protein free). Dilute Zombie NIR™ dye at 1:100-1000 in PBS. Resuspend 1-10 x 106 cells in diluted 100 µL Zombie NIR™ solution. To minimize background staining of live cells, titrate the amount of dye and/or number of cells per 100 µL for optimal performance. Different cell types can have a wide degree of variability in staining based on cell size and degree of cell death. Note: Don’t use Tris buffer as a diluent and be sure that the PBS does not contain any other protein like BSA or FBS. Note: The amount of dye used can also influence the ability to detect apoptotic as well as live and dead cells. Incubate the cells at room temperature (or 4°C), in the dark, for 15-30 minutes. Wash one time with 2 mL BioLegend’s Cell Staining Buffer (Cat. No. 420201) or equivalent buffer containing serum or BSA. Continue performing antibody staining procedure as desired. Cells can be fixed with paraformaldehyde or methanol prior to permeabilization or can be analyzed without fixation. No-wash Sequential Staining Protocol: Wash cells with PBS buffer (no Tris buffer and protein free). For reconstitution, pre-warm the kit to room temperature; add 100 µL of DMSO to one vial of Zombie NIR™ dye and mix until fully dissolved Determine the total µL volume of antibody cocktail previously titrated and optimized for the assay that will be added to each vial/well of cells based on a final volume of 100 µL. Subtract that antibody volume from the 100 µL total staining volume intended for the assay. In the remaining volume, dilute Zombie NIR™ dye at 1:100-1000 in PBS as determined by prior optimization at that volume. For example, if you are adding 20 µL of antibody cocktail for a 100 µL total staining volume, use 80 µL of Zombie NIR™ solution. Resuspend 1-10 x 106 cells in the appropriate volume of Zombie NIR™ solution. Different cell types can have a wide degree of variability in staining based on cell size and degree of cell death. Note: Don’t use Tris buffer as a diluent and be sure that the PBS does not contain any other protein like BSA or FBS. Note: The amount of dye used can also influence the ability to detect apoptotic as well as live and dead cells. Incubate for 10-15 minutes at RT (or 4°C), protected from light. Without washing the cells, add the cell surface antibody cocktail and incubate for another 15-20 minutes. Add 1-2 mL Cell Staining Buffer (Cat. No. 420201) or equivalent buffer containing BSA or serum. Centrifuge to pellet. Continue with normal fixation and permeabilization procedure. If planning to skip fixation and analyze cells live, complete an additional wash step to minimize any unnecessary background of the live cells. Notes: If the cell type in use cannot tolerate a protein-free environment, then titrate the Zombie NIR™ dye in the presence of the same amount of BSA/serum as will be present in the antibody staining procedure. A higher amount of Zombie NIR™ may be required since the BSA/serum will react with and bind up some proportion of the Zombie NIR™.
Additional Product Notes: View more applications data for this product in our Scientific Poster Library.
Application References(PubMed link indicates BioLegend citation): McMaster SR, et al. 2015. PLoS One. 10:115725. PubMed Prado-Garcia H, et al. 2015. Anticancer Res.35:1529. PubMed Rodriguez-Rodriguez N, et al. 2015. J Immunol. 194:4207. PubMed Flies DB, et al. 2015. J Immunol. 194:5294. PubMed
Product Citations: Headley M, et al. 2016. Nature. 531:513-517. PubMed Wang L, et al. 2020. Front Cell Dev Biol. 0.745138889. PubMed Iyer S, et al. 2021. Cancer Discov. 0.725. PubMed Komuczki J, et al. 2019. Immunity. 50:1289. PubMed Rad S M AH, et al. 2020. PLoS One. 15:e0232915. PubMed Pandey SP, et al. 2022. Cell Host Microbe. 30:1003. PubMed Knelson EH, et al. 2022. Cancer Immunol Res. 10:947. PubMed Sun Y, et al. 2022. STAR Protoc. 3:101479. PubMed Edwards KJ, et al. 2022. Cancer Immunol Res. 10:1084. PubMed Park G, et al. 2023. Photochem Photobiol. 99:850. PubMed Zhao Y, et al. 2022. J Neurosci. . PubMed Lutz EA, et al. 2022. Proc Natl Acad Sci U S A. 119:e2205983119. PubMed Sauter M, et al. 2022. STAR Protoc. 3:101664. PubMed Terminel MN, et al. 2022. BMC Neurosci. 23:58. PubMed Tan GMY, et al. 2022. Cancers (Basel). 14:. PubMed Prochazka L, et al. 2022. Mol Syst Biol. 18:e10886. PubMed Egli J, et al. 2022. MAbs. 14:2143009. PubMed Han X, et al. 2022. Nutrients. 14:. PubMed Li Y, et al. 2023. Adv Mater. 35:e2208923. PubMed Schönberger K, et al. 2023. Anal Chem. 95:4325. PubMed Tschanz F, et al. 2021. Cancer Res Commun. 1:164. PubMed Liu HJ, et al. 2023. Nat Commun. 14:1214. PubMed Tan J, et al. 2023. Acta Pharm Sin B. 13:632. PubMed Muri J, et al. 2023. Nat Immunol. 24:604. PubMed Zhou P, et al. 2023. Immunity. 56:669. PubMed Ananya A, et al. 2023. Immun Ageing. 20:10. PubMed Pasqual G, et al. 2023. Methods Mol Biol. 2618:71. PubMed Luo X, et al. 2023. Methods Mol Biol. 2618:133. PubMed Jiang X, et al. 2023. J Clin Invest. 133:. PubMed Pankhurst TE, et al. 2023. Cell Rep. 42:112310. PubMed Martins Nascentes Melo L, et al. 2023. J Immunother Cancer. 11:. PubMed Zhang YN, et al. 2023. Nat Commun. 14:1985. PubMed Onyshchenko K, et al. 2023. Nat Commun. 14:2087. PubMed Xu Z, et al. 2023. Cancers (Basel). 15:. PubMed Liu L, et al. 2023. J Exp Clin Cancer Res. 42:85. PubMed Glasner A, et al. 2023. Nat Immunol. 24:1020. PubMed Sugita M, et al. 2023. Cell Death Dis. 14:305. PubMed Lee K, et al. 2023. JCI Insight. 8:. PubMed Gao Y, et al. 2023. iScience. 26:106729. PubMed Changsheng H, et al. 2023. Sci Adv. 9:eade4186. PubMed Villalba N, et al. 2023. J Neuroinflammation. 20:127. PubMed Meckler JF, et al. 2023. Cancer Immunol Immunother. . PubMed Imai H, et al. 2023. iScience. 26:106822. PubMed Braun DJ, et al. 2023. PLoS One. 18:e0286495. PubMed Zhang TR, et al. 2023. Pharmaceuticals (Basel). 16:. PubMed Li JD, et al. 2023. Front Immunol. 14:1186393. PubMed Wu L, et al. 2023. Cell Res. . PubMed Cansever D, et al. 2023. Nat Immunol. . PubMed Liu X, et al. 2023. J Neuroinflammation. 20:144. PubMed Kim MY, et al. 2021. JCI Insight. 6:. PubMed Martínez-Vélez N, et al. 2022. Mol Cancer Ther. 21:471. PubMed Baratchart E, et al. 2022. PLoS Comput Biol. 18:e1009839. PubMed Luo J, et al. 2022. J Nanobiotechnology. 20:228. PubMed Rosina M, et al. 2022. Cell Metab. 34:533. PubMed Hsu MA, et al. 2022. Cancer Immunol Immunother. :. PubMed Zheng J, et al. 2022. Front Pharmacol. 13:866228. PubMed Wu R, et al. 2022. J Dermatol. 49:432. PubMed Wang W, et al. 2022. Dev Cell. 57:228. PubMed Chaurio RA, et al. 2022. Immunity. 55:115. PubMed Cautivo KM, et al. 2022. Immunity. 55:254. PubMed Kuloglu ZE, et al. 2022. Allergy. 77:2459. PubMed Bayley R, et al. 2022. Mol Cell. 82:1924. PubMed Rodriguez-Tirado C, et al. 2022. Cancer Res. 82:2313. PubMed Tang Q, et al. 2022. Mol Ther. 30:2709. PubMed Gideon HP, et al. 2022. Immunity. 55:827. PubMed Zhang Y, et al. 2022. Nat Med. 28:1421. PubMed Sudmeier LJ, et al. 2022. Cell Rep Med. 3:100620. PubMed Naseem MU, et al. 2022. J Gen Physiol. 154: . PubMed Vukovic N, et al. 2022. J Biol Chem. 298:102153. PubMed Berger G, et al. 2022. Proc Natl Acad Sci U S A. 119:e2111003119. PubMed Hsieh T, et al. 2022. Front Immunol. 13:901030. PubMed Werder RB, et al. 2022. Sci Adv. 8:eabo6566. PubMed Zhu Y, et al. 2022. Immunology. 167:576. PubMed Ostendorf BN, et al. 2022. Nature. 611:346. PubMed Wang Z, et al. 2022. J Exp Med. 219: . PubMed Naranjo S, et al. 2022. Genes Dev. 36:936. PubMed Buckner CM, et al. 2022. Cell. 185:4333. PubMed VanDyke D, et al. 2022. Cell Rep. 41:111478. PubMed Wang W, et al. 2022. Cell Rep. 41:111582. PubMed Ogishi M, et al. 2023. J Exp Med. 220: . PubMed Zhu H, et al. 2023. Clin Transl Radiat Oncol. 38:138. PubMed Schaefer-Babajew D, et al. 2023. Nature. 613:735. PubMed Edwards SC, et al. 2023. J Exp Med. 220: . PubMed Naylor G, et al. 2022. Cancers (Basel). 14: . PubMed Ronning KE, et al. 2022. J Neuroinflammation. 19:299. PubMed Pleuger C, et al. 2022. Elife. 11: . PubMed Dutt TS, et al. 2022. Cell Rep. 41:111783. PubMed Xu Q, et al. 2023. Nat Immunol. 24:186. PubMed Hägglöf T, et al. 2023. Cell. 186:147. PubMed Schepers M, et al. 2023. Brain Behav Immun. 109:1. PubMed Gauthier L, et al. 2023. Nat Biotechnol. :. PubMed Ali LR, et al. 2023. J Exp Med. 220: . PubMed Zhou H, et al. 2023. Front Immunol. 13:1059687. PubMed Vyas M, et al. 2023. Front Immunol. 13:1098445. PubMed Rosain J, et al. 2023. Cell. 186:621. PubMed Ernst MPT, et al. 2023. Hemasphere. 7:e824. PubMed Babl N, et al. 2023. Front Oncol. 13:1107484. PubMed Dragan M, et al. 2022. J Invest Dermatol. 142:583. PubMed Parida PK, et al. 2022. Cell Metab. 34:90. PubMed Ma Y, et al. 2022. Am J Physiol Heart Circ Physiol. 322:H622. PubMed Salmon AJ, et al. 2022. Cancer Immunol Res. 10:597. PubMed Nelson LJ, et al. 2022. Cell Cycle. 21:1103. PubMed Kania AK, et al. 2022. J Immunol. 208:1873. PubMed Xu Y, et al. 2022. Bio Protoc. 12:e4354. PubMed McCafferty S, et al. 2022. Mol Ther. 30:2968. PubMed Liu Y, et al. 2022. Signal Transduct Target Ther. 7:347. PubMed Sheikh BN, et al. 2020. Nat Cell Biol. 22:828. PubMed Pathak JL, et al. 2021. Front Cell Dev Biol. 628139:9. PubMed Jiang C, et al. 2020. Int J Biol Sci. 2.802083333. PubMed Qiu J, et al. 2020. Cell Rep. 33:108465. PubMed Sagami S, et al. 2017. PLoS One. 10.1371/journal.pone.0169681. PubMed Lentucci C, et al. 2017. J Biol Chem. 292:2754-2772. PubMed Montes de Oca M, et al. 2016. Cell Rep. 17:399-412. PubMed Marco Barros R, et al. 2016. Cell. 167: 203-218. PubMed Gibb D, et al. 2016. EBioMedicine. 9: 77-86. PubMed Kallemeijn WW, et al. 2019. Cell Chem Biol. 26:892. PubMed Kollareddy M, et al. 2017. Cancer Lett. 10.1016/j.canlet.2017.05.027. PubMed Ajoge HO, et al. 2022. Viruses. 14:. PubMed Tan L, et al. 2022. Biochem Biophys Rep. 32:101351. PubMed Li Q, et al. 2022. Cell Rep. 40:111308. PubMed He C, et al. 2022. Sci Adv. 8:eabm4552. PubMed Otano I, et al. 2021. Nat Commun. 12:7296. PubMed Zhou J, et al. 2021. Int J Med Sci. 18:3516. PubMed Landry LG, et al. 2021. Bio Protoc. 11:e3883. PubMed Barros-Martins J, et al. 2021. Nat Med. 27:1525. PubMed Nordengrün M, et al. 2021. Front Immunol. 12:651060. PubMed Roberts A, et al. 2021. Sci Rep. 11:4030. PubMed Ma Q, et al. 2021. Clin Transl Immunology. 10:e1300. PubMed Aguilera T, et al. 2016. Nat Commun. 7:13898. PubMed Jimenez-Duran G, et al. 2020. EBioMedicine. 61:103039. PubMed Li JY, et al. 2020. J Clin Invest. 130:1767. PubMed Kilens S, et al. 2018. Nat Commun. 9:360. PubMed Merz SF, et al. 2019. Nat Commun. 10:2312. PubMed Barry KC, et al. 2018. Nat Med. 24:1178. PubMed Karlen SJ, et al. 2018. J Neuroinflammation. 15:344. PubMed Vishnoi M, et al. 2018. Cancer Res. 78:5349. PubMed Sauter M, et al. 2022. iScience. 25:103677. PubMed Stegelmeier AA, et al. 2022. Biomedicines. 10:. PubMed Chen L, et al. 2022. Mol Ther Oncolytics. 24:522. PubMed Sneller MC, et al. 2022. Nature. 606:375. PubMed Hamminger P, et al. 2021. J Autoimmun. 119:102610. PubMed Hu W, et al. 2021. Nat Immunol. 22:1163. PubMed Schalbetter SM, et al. 2022. Sci Adv. 8:eabi6672. PubMed Abou-Hamad J, et al. 2022. iScience. 25:105524. PubMed Agudelo M, et al. 2021. J Exp Med. :218. PubMed Gaebler C, et al. 2021. Nature. 639:591. PubMed Olingy C, et al. 2017. Sci Rep. 10.1038/s41598-017-00477-1. PubMed AC Belkina, JE Snyder-Cappione 2017. Cytometry A. 91:175-179. PubMed Kodumudi KN, et al. 2019. Front Immunol. 10:1939. PubMed Liu HJ, et al. 2018. JCI Insight. 3. PubMed Zou L, et al. 2022. Brain Behav Immun. 100:10. PubMed Son ET, et al. 2021. J Clin Invest. 131:. PubMed Majstrowicz K, et al. 2021. J Cell Sci. 134:. PubMed Daniel S, et al. 2021. Infect Immun. 89:e0016521. PubMed van der Heide V, et al. 2022. Cell Rep. :110508. PubMed Michaud D, et al. 2022. Front Immunol. 12:745873. PubMed Nagatake T, et al. 2022. Mucosal Immunol. 15:289. PubMed Watters JM, et al. 2021. Biochem Biophys Res Commun. 534:773. PubMed Fitzgerald AA, et al. 2021. J Immunother Cancer. 9:. PubMed Bouffi C, et al. 2015. J Immunol. 195: 2683-2695. PubMed Higuchi T, et al. 2015. Cancer Immunol Res. 3: 1257 - 1268. PubMed Woodruff MC, et al. 2020. Nat Immunol. 1.920833333. PubMed Xu AQ, et al. 2020. Elife. 9:00. PubMed Si Y, et al. 2020. Sci Adv. 6:eaba0995. PubMed Pan H, et al. 2020. Mol Psychiatry. . PubMed Guarnaccia AD, et al. 2021. Cell Rep. 108636:34. PubMed García Nores GD, et al. 2018. Nat Commun. 9:1970. PubMed Verma M, et al. 2018. Cell Stem Cell. 23:530. PubMed Weisberg SP, et al. 2020. Cell Reports. 29(12):3916-3932.e5.. PubMed Fukushima T, et al. 2019. Cell Rep. 29:4144. PubMed Hering L, et al. 2021. Int J Mol Sci. 22:. PubMed Halim L, et al. 2022. Front Immunol. 13:836549. PubMed Hemkemeyer SA, et al. 2020. J Biol Chem. 296:100136. PubMed Massafra V, et al. 2021. J Immunol. 207:493. PubMed Agudelo M, et al. 2022. J Exp Med. 219:. PubMed Glaubitz J, et al. 2022. Nat Commun. 13:4502. PubMed Woodruff MC, et al. 2022. Nature. :. PubMed Patricio DO, et al. 2022. Front Immunol. 13:1042463. PubMed Ostendorf BN, et al. 2020. Nat Med. 26:1048. PubMed Akiyama H, et al. 2020. J Virol. . PubMed Sperber HS, et al. 2020. FASEB J. 14615:34. PubMed Moreau GB, et al. 2020. Am J Trop Med Hyg. 103:1215. PubMed Kienzl M, et al. 2020. Oncoimmunology. 9:1776059. PubMed Jenkins RW, et al. 2018. Cancer Discov. 8:196. PubMed Retamal‐Díaz A, et al. 2017. Front Immunol. . 10.3389/fimmu.2017.01523. PubMed Wlodarska M et al. 2017. Cell host & microbe. 22(1):25-37 . PubMed Beatson RE, et al. 2021. Cell Rep Med. 2:100473. PubMed Mahmoud W, et al. 2021. Cell Tissue Res. Online ahead of print. PubMed Cousin N, et al. 2021. Cancer Res. 81:4133. PubMed Chan JA, et al. 2020. Cell Rep Med. 1:100157. PubMed Michaud D, et al. 2020. Cytokine. 125:154817. PubMed Simonneau M, et al. 2018. Oncotarget. 9:36457. PubMed Koizumi SI, et al. 2018. Nat Commun. 9:5344. PubMed Miller EB, et al. 2021. J Neuroinflammation. 18:235. PubMed Mills C, et al. 2022. Cells. 11:. PubMed Pettinato G, et al. 2021. Sci Adv. 7:. PubMed Godoy-Pacheco A, et al. 2022. Oncol Lett. 24:288. PubMed Rao X, et al. 2022. Cell Death Dis. 13:891. PubMed Sato R, et al. 2020. Int Immunol. 499:32. PubMed Aregger M, et al. 2020. Nat Metab. 0.429861111. PubMed Alshetaiwi H, et al. 2020. Sci Immunol. 5:00. PubMed PRADO-GARCIA H, et al. 2015. Anticancer Res. 35:1529. PubMed Lisk C, et al. 2020. Front Immunol. 1.329166667. PubMed Yang S, et al. 2019. Nat Commun. 10:2782. PubMed Casella G, et al. 2017. Sci Rep. . 10.1038/s41598-017-16702-w. PubMed Adamik J, et al. 2022. Nat Commun. 13:5184. PubMed Sodji QH, et al. 2022. Cancer Res Commun. 2:725. PubMed Zhang Z, et al. 2021. Acta Pharm Sin B. 11:1965. PubMed Mahadevan NR, et al. 2021. Cancer Discov. 11:1952. PubMed Alansary M, et al. 2021. Dent Traumatol. 37:90. PubMed Le X, et al. 2021. J Thorac Oncol. 16:583. PubMed Song D, et al. 2021. Sci Rep. 11:22966. PubMed Aires V, et al. 2021. Front Immunol. 12:684430. PubMed Choi JE, et al. 2021. Nat Metab. 3:182. PubMed Ajina R, et al. 2021. Cancer Immunol Res. 9:386. PubMed Steinbach K, et al. 2016. J Exp Med. 213: 1571 - 1587. PubMed Bogie JF, et al. 2020. Ther Adv Chronic Dis. 11:2040622320947378. PubMed Xie Z, et al. 2020. Light Sci Appl. 0.486805556. PubMed Wang Z, et al. 2021. bioRxiv. . PubMed Wang K, et al. 2018. Medicine (Baltimore). 97:e0710. PubMed Schadt L, et al. 2020. Cell Reports. 29(5):1236-1248.e7.. PubMed Grandclaudon M, et al. 2019. Cell. 179:432. PubMed Littwitz-Salomon E, et al. 2021. Nat Commun. 12:5376. PubMed Thyrsted J, et al. 2021. iScience. 24:103300. PubMed Basu A, et al. 2021. Cancer Immunol Res. Online ahead of print. PubMed Viant C, et al. 2021. J Exp Med. 218:. PubMed Nakajima T, et al. 2021. J Exp Med. 218:. PubMed Jie X, et al. 2022. J Immunother Cancer. 10:. PubMed Ferrer-Font L, et al. 2021. Curr Protoc. 1:e222. PubMed Li Y, et al. 2022. J Neuroinflammation. 19:261. PubMed Woodruff M, et al. 2020. medRxiv. . PubMed McHugh D, et al. 2020. Life Sci Alliance. 3:00. PubMed Tavazoie MF, et al. 2018. Cell. 172:825. PubMed English KG, et al. 2022. Biomedicines. 10:. PubMed Yang J, et al. 2022. Microbiome. 10:149. PubMed Stinson WA, et al. 2022. JCI Insight. 7:. PubMed Kim S, et al. 2022. Redox Biol. 54:102347. PubMed Luo J, et al. 2022. J Nanobiotechnology. 20:228. PubMed Zeng Q, et al. 2022. Front Immunol. 13:740805. PubMed Christopher GA, et al. 2021. Biomolecules. 12:. PubMed Cho A, et al. 2021. Nature. Online ahead of print. PubMed Clapes T, et al. 2021. Nat Cell Biol. 23:704. PubMed Johnson AM, et al. 2020. J Immunol. 204:2295. PubMed Thompson EA, et al. 2021. Cell Rep. 108863:34. PubMed Espinoza J, et al. 2017. Oxidative Medicine and Cellular Longevity. 10.1155/2017/6781872. PubMed Pinder C, et al. 2017. J Immunol. 10.4049/jimmunol.1701253. PubMed Popay TM, et al. 2021. Elife. 10: . PubMed Wan G, et al. 2021. Sci Rep. 11:22121. PubMed Hills LB, et al. 2021. J Immunol. 206:89. PubMed Kuhn JA, et al. 2021. Elife. 10:. PubMed Bosnjak B, et al. 2021. Front Immunol. 12:772240. PubMed Xu Y, et al. 2021. Front Immunol. 12:666991. PubMed Zhang H, et al. 2021. Cell Rep. 36:109708. PubMed Zhu S, et al. 2022. J Oncol. 2022:8724933. PubMed Liu Y, et al. 2022. Front Oncol. 12:1037934. PubMed Scharer CD, et al. 2020. Nat Commun. 3989:11. PubMed Rodríguez-Rodríguez N, et al. 2015. J Immunol. 194:4207. PubMed Nagatake T, et al. 2018. Int Immunol. 30:471. PubMed Ito Y, et al. 2018. Cell. 174:636. PubMed Lim JME, et al. 2022. Cell Rep Med. 3:100793. PubMed Vanekova L, et al. 2022. Methods Protoc. 5:. PubMed Elias G, et al. 2022. Elife. 11:. PubMed Cohen CA, et al. 2021. Nat Commun. 12:4678. PubMed Ruibal P, et al. 2016. Nature. 533: 100-104. PubMed Muthalagu N, et al. 2020. Cancer Discov. 1.022222222. PubMed Evgin L, et al. 2020. Nat Commun. 2.671527778. PubMed Hemkemeyer SA, et al. 2020. J Biol Chem. . PubMed van Vloten JP, et al. 2019. Mol Ther Methods Clin Dev. 13:154. PubMed Akuffo AA, et al. 2018. J Biol Chem. 293:6187. PubMed Morganti JM, et al. 2019. J Neuroinflammation. 16:98. PubMed McGinnis CS, et al. 2019. Nat Methods. 1.096527778. PubMed Günther T, et al. 2019. PLoS Pathog. 15:e1007838. PubMed Fujimoto N, et al. 2020. PLoS Biol. 18:e3000704. PubMed Meyrath M, et al. 2020. Nat Commun. 2.564583333. PubMed Luo G, et al. 2021. Sci Rep. 11:7841. PubMed Braun DA, et al. 2021. Cancer Cell. 39:632. PubMed Cui Z, et al. 2021. Cell Death Dis. 12:775. PubMed Mudd PA, et al. 2022. Cell. 185:603. PubMed Valestrand L, et al. 2022. Am J Pathol. . PubMed Espinal A, et al. 2022. Int J Mol Sci. 23:. PubMed Evgin L, et al. 2022. Sci Transl Med. 14:eabn2231. PubMed Jalloh S, et al. 2022. PLoS Pathog. 18:e1010479. PubMed Soley BDS, et al. 2020. Br J Pharmacol. 177:3535. PubMed Lo CH, et al. 2021. Sci Rep. 6055:11. PubMed Salazar Y, et al. 2020. J Clin Invest. 130:3560. PubMed Bhattacharya P, et al. 2020. Elife. 9:00. PubMed Grubiši? V, et al. 2020. Cell Rep. 32:108100. PubMed Shim K, et al. 2017. Mol Ther. 10.1016/j.ymthe.2017.01.023. PubMed Tomić A, et al. 2016. PLoS Pathog. 12:e1006015. PubMed Filiano A, et al. 2016. Nature. 535:425-429. PubMed Armbruster N, et al. 2016. J Immunol. 196: 1284 - 1292. PubMed Ramachandran P, et al. 2019. Nature. 575:512. PubMed Xueyang Yu et al. 2017. Immunity. 47(5):903-912 . PubMed Nagatake T, et al. 2018. J Allergy Clin Immunol. 142:470. PubMed Waight JD, et al. 2018. Cancer Cell. 33:1033. PubMed Tajima M, et al. 2022. Curr Protoc. 2:e540. PubMed Qadir AS, et al. 2021. iScience. 24:103348. PubMed Lozano-Ojalvo D, et al. 2021. Cell Rep. 36:109570. PubMed Dieterle ME, et al. 2021. Elife. 10:. PubMed Sharma V, et al. 2021. ACR Open Rheumatol. 3:277. PubMed Clement CC, et al. 2021. Immunity. 54:721. PubMed Zhang YN, et al. 2021. Sci Adv. 7:eabj3107. PubMed Manouchehri N, et al. 2021. Proc Natl Acad Sci U S A. 118:. PubMed Mohammadi MR, et al. 2021. Commun Biol. 4:685. PubMed Noort RJ, et al. 2021. Front Cell Dev Biol. 9:659397. PubMed Cloarec R, et al. 2016. PLoS One. 11: 0160176. PubMed Rouleau N, et al. 2020. Immunohorizons. 0.695833333. PubMed Rizvi F, et al. 2021. Nat Commun. 0.925694444. PubMed Herland A, et al. 2020. Nat Biomed Eng. 421:4. PubMed Oherle K, et al. 2020. Immunity. 275:52. PubMed Zhang Y, et al. 2018. Front Microbiol. 9:2967. PubMed Grajchen E, et al. 2020. J Neuroinflammation. 0.863888889. PubMed Wang Z, et al. 2021. Nature. 592:616. PubMed Ramos MIP, et al. 2021. Elife. 10:. PubMed Su Y, et al. 2021. Clin Cancer Res. :clincanres.2241.2021. PubMed Dudek M, et al. 2021. Nature. 592:444. PubMed Jacobsen H, et al. 2021. Nat Commun. 12:4957. PubMed Cillo AR, et al. 2021. Cell Rep Med. 2:100476. PubMed Janssen JJE, et al. 2022. Am J Physiol Endocrinol Metab. 322:E141. PubMed Wang Z, et al. 2022. J Exp Med. 219:. PubMed He Y, et al. 2022. Cells. 11:. PubMed Karanika S, et al. 2022. Front Immunol. 13:972266. PubMed Luo L, et al. 2021. J Neuroinflammation. 18:27. PubMed Suzuki T, et al. 2017. Cell Rep. 18(8):2045-2057. PubMed McMaster S, et al. 2015. PLoS One. 10:115725. PubMed Ghezraoui H, et al. 2018. Nature. 560:122. PubMed Manuszak C, et al. 2020. J Biol Methods. 7:e131. PubMed McKenzie MD, et al. 2019. Cell Stem Cell. 25:258. PubMed Zischke J, et al. 2017. PLoS Pathogens. 13(6):e1006454. PubMed Reuschl AK, et al. 2022. Cell Rep. 39:110650. PubMed Tang JS, et al. 2022. Front Immunol. 13:946713. PubMed Wang Z, et al. 2021. Nature. 595:426. PubMed Mumby MJ, et al. 2021. J Virol. 95:e0058821. PubMed Chou TW, et al. 2021. Cell Death Dis. 12:756. PubMed Leary N, et al. 2022. J Extracell Vesicles. 11:e12197. PubMed Hobbs BE, et al. 2021. Pathogens. 10:. PubMed Fan ZP, et al. 2021. Front Immunol. 12:743354. PubMed Lien TS, et al. 2021. Front Immunol. 12:618577. PubMed Phan TS, et al. 2021. Sci Adv. 7:. PubMed Flies D, et al. 2015. J Immunol. 194:5294. PubMed Hering L, et al. 2020. Front Immunol. 1.747222222. PubMed Korin B, et al. 2020. Sleep. :43. PubMed Santopaolo M, et al. 2021. Front Immunol. 609406:12. PubMed Daniels M, et al. 2017. Sci Rep.. 10.1038/s41598-017-17387-x. PubMed Renner K, et al. 2020. Cell Reports. 29(1):135-150.e9.. PubMed Donlan AN, et al. 2021. JCI Insight. 6: . PubMed Lisk C, et al. 2021. Front Immunol. 12:624197. PubMed Wang R, et al. 2022. J Immunother Cancer. 10:. PubMed Denoth-Lippuner A, et al. 2021. Cell Stem Cell. 28:2020. PubMed Zhang Y, et al. 2022. Mater Today Bio. 15:100317. PubMed Smith KJ, et al. 2022. PLoS Biol. 20:e3001554. PubMed Madsen CS, et al. 2022. Commun Biol. 5:888. PubMed Maas RR, et al. 2021. Nat Protoc. 16:4692. PubMed Lee HY, et al. 2021. Curr Protoc. 1:e272. PubMed Mujal AM, et al. 2022. Cancer Immunol Res. 10:403. PubMed Chou DB, et al. 2022. Nat Commun. 13:6021. PubMed Gaebler C, et al. 2020. bioRxiv. . PubMed Shimada BK, et al. 2020. Immunohorizons. 0.55625. PubMed Jeffery H, et al. 2017. Clin Exp Immunol. 10.1111/cei.12940. PubMed Hosking M, Flynn C, Whitton J 2016. PLoS Pathog. 12: 1005861. PubMed Bryan AF, et al. 2020. Nucleic Acids Res. 48:2924. PubMed Sontheimer-Phelps A, et al. 2019. Cell Mol Gastroenterol Hepatol. 9:507. PubMed Han P, et al. 2020. Sci Adv. 6:eaaz1580. PubMed Eckert EC, et al. 2020. Mol Ther Oncolytics. 0.710416667. PubMed Chakraborty A, et al. 2022. Methods Mol Biol. 2442:565. PubMed Li X, et al. 2022. Oncoimmunology. 11:2118210. PubMed Kiesel VA, et al. 2022. Front Oncol. 12:767479. PubMed Gutierrez-Prat N, et al. 2022. Life Sci Alliance. 5:. PubMed Viant C, et al. 2020. Cell. 183:1298. PubMed Heckler M, et al. 2021. Cancer Discov. Online ahead of prin. PubMed Maller O, et al. 2020. Nat Mater. 20:548. PubMed Chou DB, et al. 2020. Nat Biomed Eng. 0.440277778. PubMed Wachowska M, et al. 2020. Cancer Immunol Immunother. 69:1101. PubMed Gangoso E, et al. 2021. Cell. 184:2454. PubMed Sibler E, et al. 2021. Cells. 10:. PubMed Qin J, et al. 2020. Cancer Immunol Res. 8:1426. PubMed Spiljar M, et al. 2021. Cell Metab. 33:2231. PubMed Kastenschmidt JM, et al. 2021. Cell Rep. 35:108997. PubMed Kerdidani D, et al. 2022. J Exp Med. 219:. PubMed Sibler E, et al. 2022. Cancers (Basel). 14:. PubMed Spath S, et al. 2022. iScience. 25:104998. PubMed Farrand K, et al. 2022. Curr Protoc. 2:e482. PubMed Clutton G, et al. 2016. Sci Rep. 6:30749. PubMed Binnewies M, et al. 2019. Cell. 177:556. PubMed Muchowicz A, et al. 2017. Eur J Cancer. 10.1016/j.ejca.2017.06.004. PubMed Quijano-Rubio A, et al. 2022. Nat Biotechnol. Online ahead of print. PubMed Patterson DG, et al. 2021. J Immunol. 207:1798. PubMed Zhang N, et al. 2022. Front Immunol. 13:926368. PubMed Cho A, et al. 2022. J Exp Med. 219:. PubMed Celias DP, et al. 2022. STAR Protoc. 3:101464. PubMed Erens C, et al. 2022. Biomedicines. 10:. PubMed Zhou P, et al. 2022. Sci Transl Med. :eabi9215. PubMed Sauler M, et al. 2022. Nat Commun. 13:494. PubMed Guarnaccia AD, et al. 2021. STAR Protoc. 2:101000. PubMed Zhang L, et al. 2021. Mol Ther. 29:744. PubMed Gamradt S, et al. 2021. iScience. 24:103312. PubMed Li H, et al. 2021. Signal Transduct Target Ther. 6:389. PubMed Goddery EN, et al. 2021. Front Immunol. 12:726421. PubMed Xie Z, et al. 2020. Light Sci Appl. 9:161. PubMed Dar HH, et al. 2021. Redox Biol. 45:102045. PubMed
Biology Area: Apoptosis/Tumor Suppressors/Cell Death, Cell Biology, Neuroscience
Gene ID: NA
Regulatory Status: RUO
Other Names: Fixable Dye, Fixable Viability Dye, Dead, Apoptosis
Q: I am concerned about the spillover I am observing from the Zombie dye into its neighboring channels.
A: Rule of thumb with Zombie dyes is to titrate them down as much as possible to fit your application. This should potentially help with spillover. Secondly, Zombie positive events represent dead cells and are typically gated out from analysis.
Q: How does the performance of your Zombie dye compare with competitors?
A: Zombie dyes have been tested against other leading competitors' fixable viability kits and given comparable results. We also highly recommend that you titrate down the amount of each dye used in order to best match the negative signals of your unstained sample and MFI- (mean fluorescence intensity) stained samples.
Q: Can I use methanol/ethanol for fixation after using a Zombie dye?
A: Yes, most fixation reagents are fine to be used with Zombie dyes. However, it should be noted that Zombie dyes can still be sensitive to reactive oxygen species. Light exposure or reagents with hydrogen peroxide can lead to free radical formation, affecting fluorescence.
Q: Can Zombie be used to determine bacteria, yeast viability?
A: We have not tested in house bacterial or yeast viability using Zombie dyes. It is not clear whether the difference between surface and intracellular signals will be significantly different in case of non mammalian cells.
Q: Can I use Zombie with cells suspension containing serum?
A: Serum is full of proteins which will sequester the dye and thereby reducing its effective concentration. The basic rule of thumb with zombie is to titrate it based on your specific condition. Titration also helps reduce the background and spillover into other channels.
Q: Can I use Zombie dyes for microscopy?
A: Zombie dyes tested in-house for microscopy applications will display data on the product technical datasheet. It should be noted that Zombie dyes may not work for dead cell discrimination in every microscopy application. Important considerations that may impact analysis are determining the signal level that constitutes a dead cell and identifying the proper plane to observe the dead cells.
Q: Why can't I fix my cells prior to using Zombie dyes?
A: The fixation process can contort and alter the membrane of cells, effectively rendering them dead. Since the ability of the Zombie dyes to stain dead cells is correlated with cell permeability, your results may no longer be a valid representation of dead versus live cells.
Q: Can I use Zombie dyes to detect apoptotic cells?
A: Yes, Zombie dyes can be used with apoptosis markers, such as Annexin V or Apotracker™ (shown below), to discriminate live, apoptotic, and dead cells.

One day-old C57BL/6 mouse thymocytes were stained with Apotracker™ Tetra Alexa Fluor® 647 and Zombie™ YG581. Zombie-dim/Apotracker™-positive cells are apoptotic, while double-positive cells are dead. Live cells are negative for both markers.
Q: How should I store Zombie dyes?
A: Store the Zombie dye kit at -20°C upon receipt. Do not open vials until needed. Once DMSO is added, use immediately or store at -20°C in a dry place and protected from light, preferably in a desiccator or in a container with desiccant for no more than one month.